DOI: https://doi.org/10.54393/tt.v7i2.310

THE THERAPIST
JOURNAL OF THERAPIES & REHABILITATION SCIENCES
https://thetherapist.com.pk/index.php/tt
ISSN (E): 2790-7406, (P): 2790-7414
Volume 07, Issue 02 (April - June 2026)



The Rise of Acellular Regenerative Aesthetics: Are Exosomes Replacing Stem Cells?

OPEN ACCESS

Bushra Bashir[1*]

[1]Department of Dermatology, Allama Iqbal Medical College, Lahore, Pakistan
bushra.b27@gmail.com

ARTICLE INFO

How to Cite:

Bashir, B. (2026). The Rise of Acellular Regenerative Aesthetics: Are Exosomes Replacing Stem Cells? The Rise of Acellular Regenerative Aesthetics. THE THERAPIST (Journal of Therapies &Amp; Rehabilitation Sciences), 7(2), 01-02. https://doi.org/10.54393/tt.v7i2.310

It is not only the discovery of new therapies but also the understanding of how the existing therapies work those results in the advancement of science. Regenerative aesthetics shifted in the last decade from stem cells to the biological messages they deliver. Just a few years back, the discussion of scientific meetings revolved around stem cells, their isolation methods, differentiation potential, and tissue regeneration. Today, the talk has markedly changed. A question has arisen: does the therapeutic value of stem cells lie in the cells themselves or in the biological messengers they produce? [1]. This change has pushed exosomes from relative anonymity to the forefront of regenerative medicine.

As clinicians, this study witnessing an unprecedented rise in interest in acellular therapies. Not only are scientific publications increasing exponentially, but the market is also bombarded with commercial products, and most importantly, patients are becoming familiar with terminology that is confined to research laboratories. This enthusiasm raised a question: Are exosomes replacing stem cells? The answer to it is perhaps very simple and even more interesting than the question itself.

Exosomes are not replacing stem cells. Instead, they are adding it to our understanding of how stem cells can achieve their therapeutic results. Mesenchymal stem cells were believed to repair tissues by trans differentiation and engraftment, but gradually, through research, it was found that they survive for a short period of time after transplantation, yet the effects of their therapeutics persist longer. This finding shifted research more towards secretomes-the collection of complex bioactive molecules released in the surrounding environment. Exosomes among these bioactive molecules gain particular attention as communicators. They influence cellular behavior, regulate the immune and inflammatory system, promote angiogenesis, collagen, and elastic fiber deposition [2].

Exosomes can be regarded as the molecular language through which stem cells communicate. I would rather say they keep certain codes of “Regenerative Language”. This concept led to a rise in acellular regenerative medicine. Stem cell transplantation is being replaced by delivering biological signals. This seems quite captivating. Stem cell treatment is scientifically very convincing, but the regulatory and logistic challenges associated with cell harvesting, expansion, transport, storage requirements, donor variability, and the costs all complicate the bedside stem cell treatment [3]. On the other side, exosome treatment can overcome many of these limitations. Exosomes can permit standardized manufacturing; they are less immunogenic, easy to store, and cannot proliferate [1, 2].

They are being used for skin rejuvenation, androgenic alopecia, acne scars, wound healing, and pigmentary disorders in dermatology [4]. They can be combined with procedures like laser resurfacing, microneedling, and fat grafting.

The greatest challenge, despite all these facts, is the gap between scientific evidence and commercial marketing. The word “exosome” has actually become more of a marketing term applied to a lot of products that are biologically entirely different, for example, conditioned media, heterogeneous extracellular vesicles and many inadequately characterized preparations. There is not only a lack of standardization in nomenclature but also in purification methods, dosage, storage, potency, and optimal donor selection. Randomized clinical trials are scarce. Therefore, a cautious approach is being adopted by regulatory authorities. To date, exosomes have not received approval from the FDA for cosmetic indications. This is important because regulatory approvals and scientific promises cannot be confused [2].

The most important misconception in the current situation is the way stem cells and exosomes are portrayed as competitors. They are actually at different positions in the same biological continuum. Stem cells cannot be replaced with exosome treatment in terms of tissue replacement, structural regeneration, or cellular repopulation. The future of regenerative medicine is not choosing one over the other; instead, it's applying each where it is biologically appropriate.

DOI: https://doi.org/10.54393/tt.v7i2.310

Engineered exosomes seem to be the future, where a combination of nanotechnology and artificial intelligence-assisted therapeutic designs is tailored to individual patients. Researchers can develop customized extracellular vesicles that can deliver selected microRNA, messenger RNA, and gene editing molecules with great precision. These innovations can reshape the whole of regenerative medicine.

As clinicians, study not only to embrace the innovation but also to commit to scientific evidence and the patient's safety. New technologies always pass through an era of enthusiasm before finding their right place.

In medicine, true progress doesn't occur by replacing one discovery over the other but the actual progress occurs by deeper biological understanding. Exosomes have not diminished the importance of stem cells but revealed the mechanism for their therapeutic achievements. The future of regenerative aesthetics, therefore, may not belong to cellular or acellular therapies alone, but to the integration of therapies guided by evidence, innovation, and an unconditional commitment to patient safety [6].

REFERENCES

[1] Hussen BM, Taheri M, Yashooa RK, Abdullah GH, Abdullah SR, Kheder RK *et al.* Revolutionizing Medicine: Recent Developments and Future Prospects in Stem-Cell Therapy. International Journal of Surgery. 2024 Dec; 110(12): 8002-24. doi: 10.1097/JS9.0000000000002109.

[2] Verma N and Arora S. Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future Directions. Pharmaceutics. 2025 Jul; 17(8): 990. doi: 10.3390/pharmaceutics17080990.

[3] Mayeen NF, Salma U, Kasim NH, Mahmoud O, Haque N. Hurdles to Overcome for Mesenchymal Stem Cell Translation from Bench to Bedside. World Journal of Stem Cells. 2025 Dec; 17(12): 114349. doi: 10.4252/wjsc.v17.i12.114349.

[4] Thakur A, Shah D, Rai D, Parra DC, Pathikonda S, Kurilova S *et al.* Therapeutic Values of Exosomes in Cosmetics, Skin Care, Tissue Regeneration, and Dermatological Diseases. Cosmetics. 2023 Apr; 10(2): 65. doi: 10.3390/cosmetics 10020065.

[5] Shirzad M, Shaban M, Mohammadzadeh V, Rahdar A, Fathi-Karkan S, Hoseini ZS *et al.* Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions. BioNanoScience. 2025 Sep; 15(3): 354. doi: 10.1007/s12668-025-01980-w.

[6] Espinal JÁ, Heredia FJ, Gómez JR, Cortez JL, Martínez ME, Prieto KJ *et al.* Next-Generation Aesthetic Surgery: Regenerative Approaches and Ethical Challenges. International Science Journal. 2025 Oct; 1(1). doi: 10.64784/005.